GlassScriptPhysician profile
Zafar A Khan
NPI 1306885025
$1,299.38
in general payments reported to CMS, 2019-2025
21 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $63.07 · 2023: $13.64 · 2024: $42.24 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.94 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $253.68 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $159.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $133.40 | 2019 | |
| Sanofi-Aventis U.S. LLC | $119.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $119.47 | 2019 | |
| Astellas Pharma US INC | $114.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $64.85 | 2024-2025 | Enhertu, Lokelma |
| Abbvie INC. | $56.35 | 2019-2025 | |
| Pfizer INC. | $41.94 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $37.80 | 2019 | |
| Gilead Sciences, INC. | $33.65 | 2019 | |
| Abbott Laboratories | $23.75 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.31 | 2025 | Lifevest |
| Inspire Medical Systems, INC. | $20.64 | 2024 | Inspire |
| Scilex Pharmaceuticals INC. | $18.65 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $17.71 | 2019 | |
| Sumitomo Pharma America, INC. | $13.64 | 2023 | Gemtesa |
| Avanir Pharmaceuticals, INC. | $12.48 | 2019 | |
| Lilly USA, LLC | $12.37 | 2019 | |
| Glaxosmithkline, LLC. | $11.26 | 2020 | |
| Eisai INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zafar Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.